img

Global Human Immunodeficiency Virus (HIV) Therapeutics Market Report, History and Forecast 2024-2034, Breakdown Data by Companies, Key Regions, Types and Application


Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Human Immunodeficiency Virus (HIV) Therapeutics Market Report, History and Forecast 2024-2034, Breakdown Data by Companies, Key Regions, Types and Application

Human Immunodeficiency Virus (HIV) Therapeutics report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Human Immunodeficiency Virus (HIV) Therapeutics market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Hospitals and Clinics are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Human Immunodeficiency Virus (HIV) Therapeutics industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Human Immunodeficiency Virus (HIV) Therapeutics key companies include ViiV Healthcare, Mylan, AbbVie, Merck & Co., Inc., Bristol-Myers Squibb Company, Boehringer Ingelheim GmbH, Genentech, Inc., Cipla, Inc. and Boehringer Ingelheim GmbH, etc. ViiV Healthcare, Mylan, AbbVie are top 3 players and held % share in total in 2022.
Human Immunodeficiency Virus (HIV) Therapeutics can be divided into NRTIs, NNRTIs, Entry and Fusion Inhibitors and Protease Inhibitors, etc. NRTIs is the mainstream product in the market, accounting for % share globally in 2022.
Human Immunodeficiency Virus (HIV) Therapeutics is widely used in various fields, such as Hospitals, Clinics and Labs,, etc. Hospitals provides greatest supports to the Human Immunodeficiency Virus (HIV) Therapeutics industry development. In 2022, global % share of Human Immunodeficiency Virus (HIV) Therapeutics went into Hospitals filed.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Human Immunodeficiency Virus (HIV) Therapeutics market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Companies, Type, Application and Regions Listed in the Report



By Company


ViiV Healthcare
Mylan
AbbVie
Merck & Co., Inc.
Bristol-Myers Squibb Company
Boehringer Ingelheim GmbH
Genentech, Inc.
Cipla, Inc.
Boehringer Ingelheim GmbH
Genentech, Inc.
Segment by Type
NRTIs
NNRTIs
Entry and Fusion Inhibitors
Protease Inhibitors
Integrase Inhibitors
Coreceptor Antagonists

Segment by Application


Hospitals
Clinics
Labs
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries

Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia

Latin America
Mexico
Brazil

Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Human Immunodeficiency Virus (HIV) Therapeutics market further
Chapter 1Global and regional market size and CAGR for the history and forecast period (2024-2024, 2024-2034).
Chapter 2Product Types and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 3Product Application and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 4Company Competition Status, Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5Companies’ Outline, covering company’s basic information, Human Immunodeficiency Virus (HIV) Therapeutics introduction, etc. Human Immunodeficiency Virus (HIV) Therapeutics Revenue and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 6 to 10Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa by revenue.
Chapter 11Market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry.
Chapter 12Mr Accuracy reports’s Conclusions of Human Immunodeficiency Virus (HIV) Therapeutics market based on comprehensive survey.
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports.

Table of Content

1 Market Overview of Human Immunodeficiency Virus (HIV) Therapeutics
1.1 Human Immunodeficiency Virus (HIV) Therapeutics Market Overview
1.1.1 Human Immunodeficiency Virus (HIV) Therapeutics Product Scope
1.1.2 Human Immunodeficiency Virus (HIV) Therapeutics Market Status and Outlook
1.2 Global Human Immunodeficiency Virus (HIV) Therapeutics Market Size Overview by Region 2024 VS 2022 VS 2034
1.3 Global Human Immunodeficiency Virus (HIV) Therapeutics Market Size by Region (2024-2034)
1.4 Global Human Immunodeficiency Virus (HIV) Therapeutics Historic Market Size by Region (2024-2024)
1.5 Global Human Immunodeficiency Virus (HIV) Therapeutics Market Size Forecast by Region (2024-2034)
1.6 Key Regions, Human Immunodeficiency Virus (HIV) Therapeutics Market Size (2024-2034)
1.6.1 North America Human Immunodeficiency Virus (HIV) Therapeutics Market Size (2024-2034)
1.6.2 Europe Human Immunodeficiency Virus (HIV) Therapeutics Market Size (2024-2034)
1.6.3 Asia-Pacific Human Immunodeficiency Virus (HIV) Therapeutics Market Size (2024-2034)
1.6.4 Latin America Human Immunodeficiency Virus (HIV) Therapeutics Market Size (2024-2034)
1.6.5 Middle East & Africa Human Immunodeficiency Virus (HIV) Therapeutics Market Size (2024-2034)
2 Human Immunodeficiency Virus (HIV) Therapeutics Market by Type
2.1 Introduction
2.1.1 NRTIs
2.1.2 NNRTIs
2.1.3 Entry and Fusion Inhibitors
2.1.4 Protease Inhibitors
2.1.5 Integrase Inhibitors
2.1.6 Coreceptor Antagonists
2.2 Global Human Immunodeficiency Virus (HIV) Therapeutics Market Size by Type: 2024 VS 2022 VS 2034
2.2.1 Global Human Immunodeficiency Virus (HIV) Therapeutics Historic Market Size by Type (2024-2024)
2.2.2 Global Human Immunodeficiency Virus (HIV) Therapeutics Forecasted Market Size by Type (2024-2034)
2.3 Key Regions Market Size by Type
2.3.1 North America Human Immunodeficiency Virus (HIV) Therapeutics Revenue Breakdown by Type (2024-2034)
2.3.2 Europe Human Immunodeficiency Virus (HIV) Therapeutics Revenue Breakdown by Type (2024-2034)
2.3.3 Asia-Pacific Human Immunodeficiency Virus (HIV) Therapeutics Revenue Breakdown by Type (2024-2034)
2.3.4 Latin America Human Immunodeficiency Virus (HIV) Therapeutics Revenue Breakdown by Type (2024-2034)
2.3.5 Middle East and Africa Human Immunodeficiency Virus (HIV) Therapeutics Revenue Breakdown by Type (2024-2034)
3 Human Immunodeficiency Virus (HIV) Therapeutics Market Overview by Application
3.1 Introduction
3.1.1 Hospitals
3.1.2 Clinics
3.1.3 Labs
3.2 Global Human Immunodeficiency Virus (HIV) Therapeutics Market Size by Application: 2024 VS 2022 VS 2034
3.2.1 Global Human Immunodeficiency Virus (HIV) Therapeutics Historic Market Size by Application (2024-2024)
3.2.2 Global Human Immunodeficiency Virus (HIV) Therapeutics Forecasted Market Size by Application (2024-2034)
3.3 Key Regions Market Size by Application
3.3.1 North America Human Immunodeficiency Virus (HIV) Therapeutics Revenue Breakdown by Application (2024-2034)
3.3.2 Europe Human Immunodeficiency Virus (HIV) Therapeutics Revenue Breakdown by Application (2024-2034)
3.3.3 Asia-Pacific Human Immunodeficiency Virus (HIV) Therapeutics Revenue Breakdown by Application (2024-2034)
3.3.4 Latin America Human Immunodeficiency Virus (HIV) Therapeutics Revenue Breakdown by Application (2024-2034)
3.3.5 Middle East and Africa Human Immunodeficiency Virus (HIV) Therapeutics Revenue Breakdown by Application (2024-2034)
4 Human Immunodeficiency Virus (HIV) Therapeutics Competition Analysis by Players
4.1 Global Human Immunodeficiency Virus (HIV) Therapeutics Market Size by Players (2024-2024)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Human Immunodeficiency Virus (HIV) Therapeutics as of 2022)
4.3 Date of Key Players Enter into Human Immunodeficiency Virus (HIV) Therapeutics Market
4.4 Global Top Players Human Immunodeficiency Virus (HIV) Therapeutics Headquarters and Area Served
4.5 Key Players Human Immunodeficiency Virus (HIV) Therapeutics Product Solution and Service
4.6 Competitive Status
4.6.1 Human Immunodeficiency Virus (HIV) Therapeutics Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 ViiV Healthcare
5.1.1 ViiV Healthcare Profile
5.1.2 ViiV Healthcare Main Business
5.1.3 ViiV Healthcare Human Immunodeficiency Virus (HIV) Therapeutics Products, Services and Solutions
5.1.4 ViiV Healthcare Human Immunodeficiency Virus (HIV) Therapeutics Revenue (US$ Million) & (2024-2024)
5.1.5 ViiV Healthcare Recent Developments
5.2 Mylan
5.2.1 Mylan Profile
5.2.2 Mylan Main Business
5.2.3 Mylan Human Immunodeficiency Virus (HIV) Therapeutics Products, Services and Solutions
5.2.4 Mylan Human Immunodeficiency Virus (HIV) Therapeutics Revenue (US$ Million) & (2024-2024)
5.2.5 Mylan Recent Developments
5.3 AbbVie
5.3.1 AbbVie Profile
5.3.2 AbbVie Main Business
5.3.3 AbbVie Human Immunodeficiency Virus (HIV) Therapeutics Products, Services and Solutions
5.3.4 AbbVie Human Immunodeficiency Virus (HIV) Therapeutics Revenue (US$ Million) & (2024-2024)
5.3.5 Merck & Co., Inc. Recent Developments
5.4 Merck & Co., Inc.
5.4.1 Merck & Co., Inc. Profile
5.4.2 Merck & Co., Inc. Main Business
5.4.3 Merck & Co., Inc. Human Immunodeficiency Virus (HIV) Therapeutics Products, Services and Solutions
5.4.4 Merck & Co., Inc. Human Immunodeficiency Virus (HIV) Therapeutics Revenue (US$ Million) & (2024-2024)
5.4.5 Merck & Co., Inc. Recent Developments
5.5 Bristol-Myers Squibb Company
5.5.1 Bristol-Myers Squibb Company Profile
5.5.2 Bristol-Myers Squibb Company Main Business
5.5.3 Bristol-Myers Squibb Company Human Immunodeficiency Virus (HIV) Therapeutics Products, Services and Solutions
5.5.4 Bristol-Myers Squibb Company Human Immunodeficiency Virus (HIV) Therapeutics Revenue (US$ Million) & (2024-2024)
5.5.5 Bristol-Myers Squibb Company Recent Developments
5.6 Boehringer Ingelheim GmbH
5.6.1 Boehringer Ingelheim GmbH Profile
5.6.2 Boehringer Ingelheim GmbH Main Business
5.6.3 Boehringer Ingelheim GmbH Human Immunodeficiency Virus (HIV) Therapeutics Products, Services and Solutions
5.6.4 Boehringer Ingelheim GmbH Human Immunodeficiency Virus (HIV) Therapeutics Revenue (US$ Million) & (2024-2024)
5.6.5 Boehringer Ingelheim GmbH Recent Developments
5.7 Genentech, Inc.
5.7.1 Genentech, Inc. Profile
5.7.2 Genentech, Inc. Main Business
5.7.3 Genentech, Inc. Human Immunodeficiency Virus (HIV) Therapeutics Products, Services and Solutions
5.7.4 Genentech, Inc. Human Immunodeficiency Virus (HIV) Therapeutics Revenue (US$ Million) & (2024-2024)
5.7.5 Genentech, Inc. Recent Developments
5.8 Cipla, Inc.
5.8.1 Cipla, Inc. Profile
5.8.2 Cipla, Inc. Main Business
5.8.3 Cipla, Inc. Human Immunodeficiency Virus (HIV) Therapeutics Products, Services and Solutions
5.8.4 Cipla, Inc. Human Immunodeficiency Virus (HIV) Therapeutics Revenue (US$ Million) & (2024-2024)
5.8.5 Cipla, Inc. Recent Developments
5.9 Boehringer Ingelheim GmbH
5.9.1 Boehringer Ingelheim GmbH Profile
5.9.2 Boehringer Ingelheim GmbH Main Business
5.9.3 Boehringer Ingelheim GmbH Human Immunodeficiency Virus (HIV) Therapeutics Products, Services and Solutions
5.9.4 Boehringer Ingelheim GmbH Human Immunodeficiency Virus (HIV) Therapeutics Revenue (US$ Million) & (2024-2024)
5.9.5 Boehringer Ingelheim GmbH Recent Developments
5.10 Genentech, Inc.
5.10.1 Genentech, Inc. Profile
5.10.2 Genentech, Inc. Main Business
5.10.3 Genentech, Inc. Human Immunodeficiency Virus (HIV) Therapeutics Products, Services and Solutions
5.10.4 Genentech, Inc. Human Immunodeficiency Virus (HIV) Therapeutics Revenue (US$ Million) & (2024-2024)
5.10.5 Genentech, Inc. Recent Developments
6 North America
6.1 North America Human Immunodeficiency Virus (HIV) Therapeutics Market Size by Country (2024-2034)
6.2 United States
6.3 Canada
7 Europe
7.1 Europe Human Immunodeficiency Virus (HIV) Therapeutics Market Size by Country (2024-2034)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Human Immunodeficiency Virus (HIV) Therapeutics Market Size by Region (2024-2034)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Human Immunodeficiency Virus (HIV) Therapeutics Market Size by Country (2024-2034)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Human Immunodeficiency Virus (HIV) Therapeutics Market Size by Country (2024-2034)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Human Immunodeficiency Virus (HIV) Therapeutics Market Dynamics
11.1 Human Immunodeficiency Virus (HIV) Therapeutics Industry Trends
11.2 Human Immunodeficiency Virus (HIV) Therapeutics Market Drivers
11.3 Human Immunodeficiency Virus (HIV) Therapeutics Market Challenges
11.4 Human Immunodeficiency Virus (HIV) Therapeutics Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List

List of Figure

List of Tables
Table 1. Global Market Human Immunodeficiency Virus (HIV) Therapeutics Market Size (US$ Million) Comparison by Region 2024 VS 2022 VS 2034
Table 2. Global Human Immunodeficiency Virus (HIV) Therapeutics Market Size by Region (2024-2024) & (US$ Million)
Table 3. Global Human Immunodeficiency Virus (HIV) Therapeutics Market Size Share by Region (2024-2024)
Table 4. Global Human Immunodeficiency Virus (HIV) Therapeutics Forecasted Market Size by Region (2024-2034) & (US$ Million)
Table 5. Global Human Immunodeficiency Virus (HIV) Therapeutics Forecasted Market Size Share by Region (2024-2034)
Table 6. Global Human Immunodeficiency Virus (HIV) Therapeutics Market Size (US$ Million) by Type: 2024 VS 2022 VS 2034
Table 7. Global Human Immunodeficiency Virus (HIV) Therapeutics Market Size by Type (2024-2024) & (US$ Million)
Table 8. Global Human Immunodeficiency Virus (HIV) Therapeutics Revenue Market Share by Type (2024-2024)
Table 9. Global Human Immunodeficiency Virus (HIV) Therapeutics Forecasted Market Size by Type (2024-2034) & (US$ Million)
Table 10. Global Human Immunodeficiency Virus (HIV) Therapeutics Revenue Market Share by Type (2024-2034)
Table 11. North America Human Immunodeficiency Virus (HIV) Therapeutics Revenue by Type (2024-2024) & (US$ Million)
Table 12. North America Human Immunodeficiency Virus (HIV) Therapeutics Revenue by Type (2024-2034) & (US$ Million)
Table 13. Europe Human Immunodeficiency Virus (HIV) Therapeutics Revenue by Type (2024-2024) & (US$ Million)
Table 14. Europe Human Immunodeficiency Virus (HIV) Therapeutics Revenue by Type (2024-2034) & (US$ Million)
Table 15. Asia-Pacific Human Immunodeficiency Virus (HIV) Therapeutics Revenue by Type (2024-2024) & (US$ Million)
Table 16. Asia-Pacific Human Immunodeficiency Virus (HIV) Therapeutics Revenue by Type (2024-2034) & (US$ Million)
Table 17. Latin America Human Immunodeficiency Virus (HIV) Therapeutics Revenue by Type (2024-2024) & (US$ Million)
Table 18. Latin America Human Immunodeficiency Virus (HIV) Therapeutics Revenue by Type (2024-2034) & (US$ Million)
Table 19. Middle East and Africa Human Immunodeficiency Virus (HIV) Therapeutics Revenue by Type (2024-2024) & (US$ Million)
Table 20. Middle East and Africa Human Immunodeficiency Virus (HIV) Therapeutics Revenue by Type (2024-2034) & (US$ Million)
Table 21. Global Human Immunodeficiency Virus (HIV) Therapeutics Market Size (US$ Million) by Application: 2024 VS 2022 VS 2034
Table 22. Global Human Immunodeficiency Virus (HIV) Therapeutics Market Size by Application (2024-2024) & (US$ Million)
Table 23. Global Human Immunodeficiency Virus (HIV) Therapeutics Revenue Market Share by Application (2024-2024)
Table 24. Global Human Immunodeficiency Virus (HIV) Therapeutics Forecasted Market Size by Application (2024-2034) & (US$ Million)
Table 25. Global Human Immunodeficiency Virus (HIV) Therapeutics Revenue Market Share by Application (2024-2034)
Table 26. North America Human Immunodeficiency Virus (HIV) Therapeutics Revenue by Application (2024-2024) & (US$ Million)
Table 27. North America Human Immunodeficiency Virus (HIV) Therapeutics Revenue by Application (2024-2034) & (US$ Million)
Table 28. Europe Human Immunodeficiency Virus (HIV) Therapeutics Revenue by Application (2024-2024) & (US$ Million)
Table 29. Europe Human Immunodeficiency Virus (HIV) Therapeutics Revenue by Application (2024-2034) & (US$ Million)
Table 30. Asia-Pacific Human Immunodeficiency Virus (HIV) Therapeutics Revenue by Application (2024-2024) & (US$ Million)
Table 31. Asia-Pacific Human Immunodeficiency Virus (HIV) Therapeutics Revenue by Application (2024-2034) & (US$ Million)
Table 32. Latin America Human Immunodeficiency Virus (HIV) Therapeutics Revenue by Application (2024-2024) & (US$ Million)
Table 33. Latin America Human Immunodeficiency Virus (HIV) Therapeutics Revenue by Application (2024-2034) & (US$ Million)
Table 34. Middle East and Africa Human Immunodeficiency Virus (HIV) Therapeutics Revenue by Application (2024-2024) & (US$ Million)
Table 35. Middle East and Africa Human Immunodeficiency Virus (HIV) Therapeutics Revenue by Application (2024-2034) & (US$ Million)
Table 36. Global Human Immunodeficiency Virus (HIV) Therapeutics Revenue (US$ Million) by Players (2024-2024)
Table 37. Global Human Immunodeficiency Virus (HIV) Therapeutics Revenue Market Share by Players (2024-2024)
Table 38. Global Top Players Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Human Immunodeficiency Virus (HIV) Therapeutics as of 2022)
Table 39. Date of Key Players Enter into Human Immunodeficiency Virus (HIV) Therapeutics Market
Table 40. Global Human Immunodeficiency Virus (HIV) Therapeutics Key Players Headquarters and Area Served
Table 41. Human Immunodeficiency Virus (HIV) Therapeutics Product Solution and Service
Table 42. Global Human Immunodeficiency Virus (HIV) Therapeutics Players Market Concentration Ratio (CR5 and HHI)
Table 43. Mergers & Acquisitions, Expansion Plans
Table 44. ViiV Healthcare Basic Information List
Table 45. ViiV Healthcare Description and Business Overview
Table 46. ViiV Healthcare Human Immunodeficiency Virus (HIV) Therapeutics Products, Services and Solutions
Table 47. Revenue (US$ Million) in Human Immunodeficiency Virus (HIV) Therapeutics Business of ViiV Healthcare (2024-2024)
Table 48. ViiV Healthcare Recent Developments
Table 49. Mylan Basic Information List
Table 50. Mylan Description and Business Overview
Table 51. Mylan Human Immunodeficiency Virus (HIV) Therapeutics Products, Services and Solutions
Table 52. Revenue (US$ Million) in Human Immunodeficiency Virus (HIV) Therapeutics Business of Mylan (2024-2024)
Table 53. Mylan Recent Developments
Table 54. AbbVie Basic Information List
Table 55. AbbVie Description and Business Overview
Table 56. AbbVie Human Immunodeficiency Virus (HIV) Therapeutics Products, Services and Solutions
Table 57. Revenue (US$ Million) in Human Immunodeficiency Virus (HIV) Therapeutics Business of AbbVie (2024-2024)
Table 58. AbbVie Recent Developments
Table 59. Merck & Co., Inc. Basic Information List
Table 60. Merck & Co., Inc. Description and Business Overview
Table 61. Merck & Co., Inc. Human Immunodeficiency Virus (HIV) Therapeutics Products, Services and Solutions
Table 62. Revenue (US$ Million) in Human Immunodeficiency Virus (HIV) Therapeutics Business of Merck & Co., Inc. (2024-2024)
Table 63. Merck & Co., Inc. Recent Developments
Table 64. Bristol-Myers Squibb Company Basic Information List
Table 65. Bristol-Myers Squibb Company Description and Business Overview
Table 66. Bristol-Myers Squibb Company Human Immunodeficiency Virus (HIV) Therapeutics Products, Services and Solutions
Table 67. Revenue (US$ Million) in Human Immunodeficiency Virus (HIV) Therapeutics Business of Bristol-Myers Squibb Company (2024-2024)
Table 68. Bristol-Myers Squibb Company Recent Developments
Table 69. Boehringer Ingelheim GmbH Basic Information List
Table 70. Boehringer Ingelheim GmbH Description and Business Overview
Table 71. Boehringer Ingelheim GmbH Human Immunodeficiency Virus (HIV) Therapeutics Products, Services and Solutions
Table 72. Revenue (US$ Million) in Human Immunodeficiency Virus (HIV) Therapeutics Business of Boehringer Ingelheim GmbH (2024-2024)
Table 73. Boehringer Ingelheim GmbH Recent Developments
Table 74. Genentech, Inc. Basic Information List
Table 75. Genentech, Inc. Description and Business Overview
Table 76. Genentech, Inc. Human Immunodeficiency Virus (HIV) Therapeutics Products, Services and Solutions
Table 77. Revenue (US$ Million) in Human Immunodeficiency Virus (HIV) Therapeutics Business of Genentech, Inc. (2024-2024)
Table 78. Genentech, Inc. Recent Developments
Table 79. Cipla, Inc. Basic Information List
Table 80. Cipla, Inc. Description and Business Overview
Table 81. Cipla, Inc. Human Immunodeficiency Virus (HIV) Therapeutics Products, Services and Solutions
Table 82. Revenue (US$ Million) in Human Immunodeficiency Virus (HIV) Therapeutics Business of Cipla, Inc. (2024-2024)
Table 83. Cipla, Inc. Recent Developments
Table 84. Boehringer Ingelheim GmbH Basic Information List
Table 85. Boehringer Ingelheim GmbH Description and Business Overview
Table 86. Boehringer Ingelheim GmbH Human Immunodeficiency Virus (HIV) Therapeutics Products, Services and Solutions
Table 87. Revenue (US$ Million) in Human Immunodeficiency Virus (HIV) Therapeutics Business of Boehringer Ingelheim GmbH (2024-2024)
Table 88. Boehringer Ingelheim GmbH Recent Developments
Table 89. Genentech, Inc. Basic Information List
Table 90. Genentech, Inc. Description and Business Overview
Table 91. Genentech, Inc. Human Immunodeficiency Virus (HIV) Therapeutics Products, Services and Solutions
Table 92. Revenue (US$ Million) in Human Immunodeficiency Virus (HIV) Therapeutics Business of Genentech, Inc. (2024-2024)
Table 93. Genentech, Inc. Recent Developments
Table 94. North America Human Immunodeficiency Virus (HIV) Therapeutics Market Size by Country (2024-2024) & (US$ Million)
Table 95. North America Human Immunodeficiency Virus (HIV) Therapeutics Market Size by Country (2024-2034) & (US$ Million)
Table 96. Europe Human Immunodeficiency Virus (HIV) Therapeutics Market Size by Country (2024-2024) & (US$ Million)
Table 97. Europe Human Immunodeficiency Virus (HIV) Therapeutics Market Size by Country (2024-2034) & (US$ Million)
Table 98. Asia-Pacific Human Immunodeficiency Virus (HIV) Therapeutics Market Size Growth Rate (CAGR) by Region (US$ Million): 2024 VS 2022 VS 2034
Table 99. Asia-Pacific Human Immunodeficiency Virus (HIV) Therapeutics Market Size by Region (2024-2024) & (US$ Million)
Table 100. Asia-Pacific Human Immunodeficiency Virus (HIV) Therapeutics Market Size by Region (2024-2034) & (US$ Million)
Table 101. Asia-Pacific Human Immunodeficiency Virus (HIV) Therapeutics Market Share by Region (2024-2024)
Table 102. Asia-Pacific Human Immunodeficiency Virus (HIV) Therapeutics Market Share by Region (2024-2034)
Table 103. Latin America Human Immunodeficiency Virus (HIV) Therapeutics Market Size Growth Rate (CAGR) by Region (US$ Million): 2024 VS 2022 VS 2034
Table 104. Latin America Human Immunodeficiency Virus (HIV) Therapeutics Market Size by Country (2024-2024) & (US$ Million)
Table 105. Latin America Human Immunodeficiency Virus (HIV) Therapeutics Market Size by Country (2024-2034) & (US$ Million)
Table 106. Middle East & Africa Human Immunodeficiency Virus (HIV) Therapeutics Market Size Growth Rate (CAGR) by Region (US$ Million): 2024 VS 2022 VS 2034
Table 107. Middle East & Africa Human Immunodeficiency Virus (HIV) Therapeutics Market Size by Country (2024-2024) & (US$ Million)
Table 108. Middle East & Africa Human Immunodeficiency Virus (HIV) Therapeutics Market Size by Country (2024-2034) & (US$ Million)
Table 109. Human Immunodeficiency Virus (HIV) Therapeutics Market Trends
Table 110. Human Immunodeficiency Virus (HIV) Therapeutics Market Drivers
Table 111. Human Immunodeficiency Virus (HIV) Therapeutics Market Challenges
Table 112. Human Immunodeficiency Virus (HIV) Therapeutics Market Restraints
Table 113. Research Programs/Design for This Report
Table 114. Key Data Information from Secondary Sources
Table 115. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Human Immunodeficiency Virus (HIV) Therapeutics Market Size Year-over-Year 2024-2034 & (US$ Million)
Figure 2. Global Human Immunodeficiency Virus (HIV) Therapeutics Market Size (US$ Million), 2024 VS 2022 VS 2034
Figure 3. Global Human Immunodeficiency Virus (HIV) Therapeutics Market Share by Regions: 2022 VS 2034
Figure 4. Global Human Immunodeficiency Virus (HIV) Therapeutics Forecasted Market Size Share by Region (2024-2034)
Figure 5. North America Human Immunodeficiency Virus (HIV) Therapeutics Market Size Growth Rate (2024-2034) & (US$ Million)
Figure 6. Europe Human Immunodeficiency Virus (HIV) Therapeutics Market Size Growth Rate (2024-2034) & (US$ Million)
Figure 7. Asia-Pacific Human Immunodeficiency Virus (HIV) Therapeutics Market Size Growth Rate (2024-2034) & (US$ Million)
Figure 8. Latin America Human Immunodeficiency Virus (HIV) Therapeutics Market Size Growth Rate (2024-2034) & (US$ Million)
Figure 9. Middle East & Africa Human Immunodeficiency Virus (HIV) Therapeutics Market Size Growth Rate (2024-2034) & (US$ Million)
Figure 10. Product Picture of NRTIs
Figure 11. Global NRTIs Market Size (US$ Million) & YoY Growth (2024-2034)
Figure 12. Product Picture of NNRTIs
Figure 13. Global NNRTIs Market Size (US$ Million) & YoY Growth (2024-2034)
Figure 14. Product Picture of Entry and Fusion Inhibitors
Figure 15. Global Entry and Fusion Inhibitors Market Size (US$ Million) & YoY Growth (2024-2034)
Figure 16. Product Picture of Protease Inhibitors
Figure 17. Global Protease Inhibitors Market Size (US$ Million) & YoY Growth (2024-2034)
Figure 18. Product Picture of Integrase Inhibitors
Figure 19. Global Integrase Inhibitors Market Size (US$ Million) & YoY Growth (2024-2034)
Figure 20. Product Picture of Coreceptor Antagonists
Figure 21. Global Coreceptor Antagonists Market Size (US$ Million) & YoY Growth (2024-2034)
Figure 22. Global Human Immunodeficiency Virus (HIV) Therapeutics Market Size Share by Type: 2022 & 2034
Figure 23. North America Human Immunodeficiency Virus (HIV) Therapeutics Revenue Market Share by Type (2024-2034)
Figure 24. Europe Human Immunodeficiency Virus (HIV) Therapeutics Revenue Market Share by Type (2024-2034)
Figure 25. Asia-Pacific Human Immunodeficiency Virus (HIV) Therapeutics Revenue Market Share by Type (2024-2034)
Figure 26. Latin America Human Immunodeficiency Virus (HIV) Therapeutics Revenue Market Share by Type (2024-2034)
Figure 27. Middle East and Africa Human Immunodeficiency Virus (HIV) Therapeutics Revenue Market Share by Type (2024-2034)
Figure 28. Hospitals Market Size (US$ Million) & YoY Growth (2024-2034)
Figure 29. Clinics Market Size (US$ Million) & YoY Growth (2024-2034)
Figure 30. Labs Market Size (US$ Million) & YoY Growth (2024-2034)
Figure 31. Global Human Immunodeficiency Virus (HIV) Therapeutics Market Size Share by Application: 2022 & 2034
Figure 32. North America Human Immunodeficiency Virus (HIV) Therapeutics Revenue Market Share by Application (2024-2034)
Figure 33. Europe Human Immunodeficiency Virus (HIV) Therapeutics Revenue Market Share by Application (2024-2034)
Figure 34. Asia-Pacific Human Immunodeficiency Virus (HIV) Therapeutics Revenue Market Share by Application (2024-2034)
Figure 35. Latin America Human Immunodeficiency Virus (HIV) Therapeutics Revenue Market Share by Application (2024-2034)
Figure 36. Middle East and Africa Human Immunodeficiency Virus (HIV) Therapeutics Revenue Market Share by Application (2024-2034)
Figure 37. Human Immunodeficiency Virus (HIV) Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2024 VS 2022
Figure 38. Global Top 5 and Top 10 Players Human Immunodeficiency Virus (HIV) Therapeutics Market Share in 2022
Figure 39. North America Human Immunodeficiency Virus (HIV) Therapeutics Market Share by Country (2024-2034)
Figure 40. United States Human Immunodeficiency Virus (HIV) Therapeutics Market Size (2024-2034) & (US$ Million)
Figure 41. Canada Human Immunodeficiency Virus (HIV) Therapeutics Market Size (2024-2034) & (US$ Million)
Figure 42. Germany Human Immunodeficiency Virus (HIV) Therapeutics Market Size (2024-2034) & (US$ Million)
Figure 43. France Human Immunodeficiency Virus (HIV) Therapeutics Market Size (2024-2034) & (US$ Million)
Figure 44. U.K. Human Immunodeficiency Virus (HIV) Therapeutics Market Size (2024-2034) & (US$ Million)
Figure 45. Italy Human Immunodeficiency Virus (HIV) Therapeutics Market Size (2024-2034) & (US$ Million)
Figure 46. Russia Human Immunodeficiency Virus (HIV) Therapeutics Market Size (2024-2034) & (US$ Million)
Figure 47. Nordic Countries Human Immunodeficiency Virus (HIV) Therapeutics Market Size (2024-2034) & (US$ Million)
Figure 48. Asia-Pacific Human Immunodeficiency Virus (HIV) Therapeutics Market Share by Region (2024-2034)
Figure 49. China Human Immunodeficiency Virus (HIV) Therapeutics Market Size (2024-2034) & (US$ Million)
Figure 50. Japan Human Immunodeficiency Virus (HIV) Therapeutics Market Size (2024-2034) & (US$ Million)
Figure 51. South Korea Human Immunodeficiency Virus (HIV) Therapeutics Market Size (2024-2034) & (US$ Million)
Figure 52. Southeast Asia Human Immunodeficiency Virus (HIV) Therapeutics Market Size (2024-2034) & (US$ Million)
Figure 53. India Human Immunodeficiency Virus (HIV) Therapeutics Market Size (2024-2034) & (US$ Million)
Figure 54. Australia Human Immunodeficiency Virus (HIV) Therapeutics Market Size (2024-2034) & (US$ Million)
Figure 55. Latin America Human Immunodeficiency Virus (HIV) Therapeutics Market Share by Country (2024-2034)
Figure 56. Mexico Human Immunodeficiency Virus (HIV) Therapeutics Market Size (2024-2034) & (US$ Million)
Figure 57. Brazil Human Immunodeficiency Virus (HIV) Therapeutics Market Size (2024-2034) & (US$ Million)
Figure 58. Middle East & Africa Human Immunodeficiency Virus (HIV) Therapeutics Market Share by Country (2024-2034)
Figure 59. Turkey Human Immunodeficiency Virus (HIV) Therapeutics Market Size (2024-2034) & (US$ Million)
Figure 60. Saudi Arabia Human Immunodeficiency Virus (HIV) Therapeutics Market Size (2024-2034) & (US$ Million)
Figure 61. UAE Human Immunodeficiency Virus (HIV) Therapeutics Market Size (2024-2034) & (US$ Million)
Figure 62. Bottom-up and Top-down Approaches for This Report